Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485170 | 0.78 | ABCB11 (0.56) | SMN1; SMN2MAPTGAAHTT | |
| SCHEMBL16841790 | 0.78 | POLB (0.49) | LMNASMN1; SMN2MAPTGAANPSR1 | |
| SCHEMBL2986775 | 0.77 | MAPT (0.56) | LMNASMN1; SMN2MAPTGAANPSR1 | |
| SCHEMBL12403856 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2RORCNR1H2NR1H3MLYCD | |
| SCHEMBL15061121 | 0.77 | MAPT (0.43) | LMNASMN1; SMN2MAPTGAAPDK1 | |
| SCHEMBL27491369 | 0.74 | CNR2 (0.43) | LMNASMN1; SMN2MAPTMAPK1HTT | |
| SCHEMBL16098804 | 0.73 | LMNA (0.50) | LMNASMN1; SMN2MAPTNPSR1NR1H2 | |
| SCHEMBL6214399 | 0.72 | LMNA (0.49) | LMNASMN1; SMN2GAARORCNR1H2 | |
| SCHEMBL19425510 | 0.71 | TSHR (0.61) | LMNASMN1; SMN2MAPTGAANPSR1 | |
| SCHEMBL2945233 | 0.71 | ALDH1A1 (0.50) | LMNASMN1; SMN2MAPTNPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900244-B2 | Anilino liver X-receptor modulators | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | claimed |
| US-20040087632-A1 | Controlling metabolism of lipids, cholesterol | PHARMACIA CORPORATION | 2004-05-06 | — | — | US | claimed |
| US-6900244-B2 | Anilino liver X-receptor modulators | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040087632-A1 | Controlling metabolism of lipids, cholesterol | PHARMACIA CORPORATION | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087632-A1 | Controlling metabolism of lipids, cholesterol | NR1H2, NR1H3, SREBF1 | LMNA 2466/4885SMN1; SMN2 4658/4885MAPT 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.